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Understanding trichloroethylene (TCE) phar-
macokinetics—the dynamic behavior of chem-
ical absorption, distribution, metabolism, and
excretion (ADME)—is critical to both the
qualitative and quantitative assessments of
human health risk from environmental expo-
sures. Qualitatively, pharmacokinetic informa-
tion can help identify the chemical species that
may be causally associated with observed toxic
responses. This is particularly important for
TCE because many of its toxic effects are
thought to be due to metabolites rather than to
TCE alone (Caldwell and Keshava 2006). In
addition the delineation of inter- and
intraspecies pharmacokinetic differences can
provide insight into how laboratory animal
and epidemiological data may inform overall
human health risks and how individual suscep-
tibility may differ. Furthermore, physiologi-
cally based pharmacokinetic (PBPK) models
can quantify the relationship between external
measures of exposure and internal measures of
toxicologically relevant dose. Selection of an
appropriate dose metric for use in risk assess-
ment depends on both an understanding of
the target tissue, active chemical agent, and
mode of action (MOA) for a particular toxic
effect [see Caldwell and Keshava (2006) and
Keshava and Caldwell (2006) for additional
MOA discussion] and the reliability of the
PBPK models themselves. The state-of-the-
science monograph on TCE health risks in
Environmental Health Perspectives (Scott and
Cogliano 2000) included reports on a number
of PBPK models for TCE and its metabolites
and on applications of these models (Barton
and Clewell 2000; Bois 2000a, 2000b; Clewell
et al. 2000; Fisher 2000; Rhomberg 2000).
The U.S. Environmental Protection Agency
(U.S. EPA), in its 2001 draft TCE assessment
(U.S. EPA 2001), used TCE PBPK models to
address a number of different risk assessment
issues, including cross-species pharmacokinetic
extrapolation of rodent studies of both cancer
and noncancer effects, exposure route extrapo-
lation, and characterization of human pharma-
cokinetic variability. 
In this article we present an updated
review of the pharmacokinetics of TCE and
its metabolites and the factors affecting
PBPK modeling, focusing on information
that has emerged since publication of the
Environmental Health Perspectives’ state-of-the-
science monograph in 2000 (Scott and
Cogliano 2000). Although some scientiﬁc con-
clusions can be drawn from this updated body
of data, speculation as to the effect of these
data on the ﬁnal TCE risk assessment would
be premature at this point, given the ongoing
National Academy of Sciences consultation
discussed in the overview article (Chiu et al.
2006) and the subsequently planned revision
of the U.S. EPA TCE risk assessment.
Therefore, this mini-monograph is a review of
recently published scientific literature in the
context of how it informs the key scientific
issues believed to be most critical to developing
a revised risk assessment. In particular, in the
present article we describe the major issues
related to the ADME of TCE and its metabo-
lites; discuss PBPK models for TCE and its
metabolites, including the four models/para-
meterizations reviewed or published in 2000
(Bois 2000a, 2000b; Clewell et al. 2000;
Fisher 2000) and several recent and ongoing
PBPK modeling efforts; and summarize the
current challenges to PBPK modeling for
application to risk assessment. 
Scientiﬁc Uncertainties in the
Pharmacokinetics of TCE and
Its Metabolites
Lash et al. (2000a) presented a comprehensive
review of the ADME of TCE and its metabo-
lites as part of the 2000 state-of-the-science
monograph on TCE health risks (Scott and
Cogliano 2000), with a summary presented in
the U.S. EPA 2001 draft risk assessment (U.S.
EPA 2001). Brieﬂy, TCE is rapidly and exten-
sively absorbed via all routes of environmental
exposure—ingestion, inhalation, and dermal
contact. Once absorbed, TCE is distributed
via the circulatory system throughout the
body. The majority of TCE taken into the
body is metabolized; direct exhalation is the
other major route of elimination of the parent
compound (Lash et al. 2000a). 
A postulated scheme for the pathways of
TCE metabolism—adapted from the work of
Lash et al. (2000a), Clewell et al. (2000), and
recent studies described later in this section—
is presented in Figure 1. As shown in the
figure, TCE and some of its subsequent
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Much progress has been made in understanding the complex pharmacokinetics of trichloroethylene
(TCE). Qualitatively, it is clear that TCE is metabolized to multiple metabolites either locally or into
systemic circulation. Many of these metabolites are thought to have toxicologic importance. In addi-
tion, efforts to develop physiologically based pharmacokinetic (PBPK) models have led to a better
quantitative assessment of the dosimetry of TCE and several of its metabolites. As part of a mini-
monograph on key issues in the health risk assessment of TCE, this article is a review of a number of
the current scientiﬁc issues in TCE pharmacokinetics and recent PBPK modeling efforts with a focus
on literature published since 2000. Particular attention is paid to factors affecting PBPK modeling
for application to risk assessment. Recent TCE PBPK modeling efforts, coupled with methodologic
advances in characterizing uncertainty and variability, suggest that rigorous application of PBPK
modeling to TCE risk assessment appears feasible at least for TCE and its major oxidative metabo-
lites trichloroacetic acid and trichloroethanol. However, a number of basic structural hypotheses
such as enterohepatic recirculation, plasma binding, and ﬂow- or diffusion-limited treatment of tis-
sue distribution require additional evaluation and analysis. Moreover, there are a number of metabo-
lites of potential toxicologic interest, such as chloral, dichloroacetic acid, and those derived from
glutathione conjugation, for which reliable pharmacokinetic data is sparse because of analytical difﬁ-
culties or low concentrations in systemic circulation. It will be a challenge to develop reliable dosime-
try for such cases. Key words: metabolism, pharmacokinetics, physiologically based pharmacokinetic
model, risk assessment, trichloroethylene. Environ Health Perspect 114:1450–1456 (2006).
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branching metabolic pathways; therefore,
assessment of its pharmacokinetics is compli-
cated. Metabolism of TCE itself occurs
through two main irreversible pathways: oxi-
dation via the microsomal mixed-function oxi-
dase (MFO) system [i.e., cytochrome P450s
(CYPs)] primarily to chloral/chloral hydrate
(CHL/CH; see the discussion below regarding
TCE-oxide) and conjugation with glutathione
(GSH) by glutathione S-transferases (GSTs)
to S-dichlorovinyl glutathione (DCVG). For
TCE oxidation, CYP2E1 is thought to be
most important in vivo. Subsequent important
metabolic branch points include the produc-
tion of trichloroethanol (TCOH) and
trichloroacetic acid (TCA) from CHL/CH;
the production of TCOH glucuronide
(TCOG) and regeneration of CHL/CH from
TCOH, and the N-acetylation versus bioacti-
vation of S-dichlorovinyl-L-cysteine (DCVC).
The major metabolites detected in blood and
urine after TCE exposure are TCOH/TCOG
and TCA, and some evidence suggests the
direct production of TCA from TCOH.
Further metabolism of these species, if any, is
not well characterized; the downstream
metabolites have not been consistently
detected in vivo. The enzyme families involved
in many of these transformations are thought
to be known. Little, if any, information is
available, however, regarding the specific
isoforms involved or the differences in their
concentrations or proportions across species,
individuals, or organs.
Important issues relating to understand-
ing TCE pharmacokinetics are discussed
below. Particularly important for risk assess-
ment is whether sufﬁcient information exists
both within and across species to quantify
rates of TCE metabolism, ﬂux through differ-
ent metabolic pathways, and distribution and
excretion of the metabolites.
Enterohepatic recirculation of TCA and
TCOH. In the liver, chemicals can be secreted
into the bile and transported into the gut,
where they are reabsorbed into the portal
blood, thereby increasing the effective half-life
for systemic clearance. Two of TCE’s oxidative
metabolites, TCA and TCOH, have been
measured in the bile of rats (Stenner et al.
1997). Bile-cannulated rats showed different
blood concentration proﬁles, providing in vivo
evidence for such recirculation. A PBPK model
based on this work (Stenner et al. 1998)
included enterohepatic recirculation (EHR)
and showed a reasonable match to rat concen-
tration proﬁles after oral doses of TCE (in 2%
Tween 80) and intravenous doses of TCA and
TCOH. Difﬁculties exist in extrapolating the
rat data to other species because biliary excre-
tion does not scale uniformly, as shown in
studies with therapeutics (Mahmood and
Sahajwalla 2002).
The signiﬁcance of recirculation on impor-
tant dose metrics is uncertain because existing
PBPK models have generally shown reasonable
ﬁts to blood and urine data without recircula-
tion. For example, even though Clewell et al.
(2000) implemented recirculation structurally,
reabsorption in the gut was set to zero for
comparison with most data. Bois (2000a)
noted, however, that urinary excretion data
for TCOG in mice was not well fit by the
Fisher model, which did not include recircu-
lation. Overall, evaluation of the model fit
and sensitivity of TCA- and TCOH-related
dose metrics with and without EHR has not
been reported. 
Diffusion-limited tissue distribution in fat
and liver. Most of the PBPK models for TCE
assume ﬂow-limited distribution of chemicals
to the organ compartments, a representation
that assumes compartments are well mixed and
that the chemical concentration in the blood
leaving the tissue has reached equilibrium with
the concentration in the tissue. However, the
fat and liver are known to be heterogeneous
tissues (e.g., Andersen et al. 1997) and impor-
tant to the distribution and metabolism of
volatile organics, respectively. 
Bois (2000a) reported that the measured
adiposity of the individual subjects from Fisher
et al. (1998) did not correlate well with the
posterior estimates for the model parameter for
percentage body weight as fat. Bois suggested
one possible explanation in that the pharmaco-
kinetic compartment for fat may not be well
estimated by external adiposity measurements,
but model error cannot be excluded. Albanese
et al. (2002) suggested that a compartmental
model for fat does not adequately capture the
concentration profile of TCE in adipose
tissue. Consequently, they developed an axial
dispersion model designed to account for
physiologic heterogeneities. These authors
compared the perfusion-limited, diffusion-
limited, and axial dispersion models and con-
cluded that the axial dispersion model is best
able to capture the physiologic heterogeneities
of adipose tissue and their expected effects on
TCE adipose concentrations. 
Keys et al. (2003) recently developed a
PBPK model for TCE parent kinetics in rats
and mice that used two-compartment descrip-
tions of the fat and liver to better fit parent
compound time-courses in those tissues. For
the fat, fat blood and fat tissue were both
explicitly modeled, with transport between
them changed from ﬂow limited to diffusion
limited. The liver was divided into a “shallow”
compartment (assumed to be the site of metab-
olism) and a “deep” compartment, with trans-
port between them via diffusion. Although the
deep compartment was proposed to represent
the lipid portion of the liver, the authors noted
that the physiologic basis for a deep liver com-
partment was not understood. Keys et al.
(2003) concluded that TCE parent concentra-
tions are better simulated by this more complex
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Figure 1. Postulated metabolism scheme for trichloroethylene. Figure adapted from Clewell et al. (2000) and Lash
et al. (2000a). For the GSH pathway, metabolism to 1,2-DCVG is shown, but 1,1-DCVG goes through similar steps through
1,1-DCVC to N-acetylated and reactive species. 
Abbreviations: ADH, alcohol dehydrogenase; BL, cysteine conjugate β-lyase; CDH, chloral dehydrogenase (aldehyde oxidase);
CGDP, cysteinyl-glycine dipeptidase; CH, chloral hydrate; CHL, chloral; DCA, dichloroacetic acid; DCVC, S-dichlorovinyl-L-cysteine;
DCVCS, 1,2-DCVC sulfoxide; DCVG, S-dichlorovinyl glutathione; EHR, enterohepatic recirculation; FA, formic acid; FMO, ﬂavin-con-
taining monooxygenase; GA, glyoxylic acid; GGTP, γ-glutamyl transpeptidase; GST, glutathione S-transferase; MCA, mono-
chloroacetic acid; MFO, mixed-function oxidase (i.e., cytochrome P450); NAT, N-acetyltransferase; NADCVC, N-acetyl-1,2-DCVC;
OA, oxalic acid; TCE-O-P450, oxygenated TCE-cytochrome P450 transition state complex; TCA, trichloroacetic acid; TCOG,





Urinemodel and that although other dose metrics
were not evaluated, metabolite concentrations
would not be expected to be significantly
changed. Lipscomb et al. (1998, 2003a) used a
ﬂow-limited PBPK model to simulate the vari-
ability in hepatic CYP2E1 content that was
measured in vitro (Lipscomb et al. 1997,
2003b; Snawder and Lipscomb 2000). The
ﬂow-limited model indicated that the ﬂux of
TCE oxidation was not sensitive to enzyme
content but was instead limited by hepatic
blood ﬂow. However, the relative contributions
of transport and metabolism in the liver may
change with a diffusion-limited description.
The importance of more complex descriptions
of both liver and fat needs to be determined
because the liver is considered to be a target
organ and the fat can store TCE. 
Plasma binding of TCA and dichloroacetic
acid. The binding of chemicals to proteins in
plasma affects their availability to other tissues
and their effective half-life in the body. The
TCE metabolites TCA and dichloroacetic acid
(DCA) bind to plasma proteins. Lumpkin
et al. (2003), Schultz et al. (1999), Templin
et al. (1995), and Yu et al. (2000) all measured
TCA binding in various species and at various
concentration ranges. Of these, Templin et al.
(1995) and Lumpkin et al. (2003) measured
levels in humans, mice, and rats. Lumpkin
et al. (2003) studied the widest concentration
range, spanning reported TCA plasma concen-
trations from experimental studies. However,
these data are not entirely consistent among
researchers; 2- to 3-fold differences are noted
in some cases, although some differences
existed in the rodent strains and experimental
protocols used. 
Schultz et al. (1999) also measured DCA
binding in rats at a single concentration of
about 100 µM and found a binding fraction
of < 10%. However, these data are not greatly
informative for TCE exposure in which DCA
levels are signiﬁcantly lower, and limitation to
a single concentration precludes fitting to
standard binding equations from which the
binding at low concentrations could be
extrapolated. Because of the observed species
differences in TCA binding, direct extrapola-
tion of the DCA rat binding data to other
species may not be accurate. 
Stenner et al. (1998) and Clewell et al.
(2004) have incorporated plasma binding of
TCA in PBPK models of TCE. The authors
assume that the tissue-bound/free ratio is in
equilibrium with blood, but only the free
fraction is available for exchange with tissues.
The binding equilibrium assumption requires
that the time scales of binding are fast relative
to the other ADME processes but slower than
the tissue perfusion time scale. However, exist-
ing studies have not reported the time scale
of DCA or TCA binding kinetics. Evaluation
of the impact of the binding uncertainties
associated with the kinetics and differing
experimental observations on the PBPK model
dose metrics has not been reported. 
DCA formation, pharmacokinetics, and the
role of trichloroethylene oxide (epoxide). Recent
data suggest that DCA is one of the TCE
metabolites involved in rodent liver tumor
induction [Bull 2000; see also discussion in
Caldwell and Keshava (2006)]. As noted by
Lash et al. (2000a), although DCA has been
reported in vivo after TCE exposure in both
mice and humans, considerable uncertainty
remains in the levels actually produced because
of known analytical limitations in the available
DCA measurements. In addition the multiple
hypotheses regarding how DCA may be formed
and the self-inhibition of its metabolism com-
plicate interpretation of these data.
Detection of DCA production in vivo
after TCE administration has been compli-
cated by reported problems with analytical
methodologies that have led to artifactual for-
mation of DCA ex vivo when samples contain
significant amounts of TCA (Ketcha et al.
1996). After the discovery of these analytical
issues, Merdink et al. (1998) reevaluated the
formation of DCA from TCE, TCOH, and
TCA in mice, with particular focus on the
hypothesis that DCA is formed from dechlori-
nation of TCA. They were unable to detect
blood DCA in naive mice after administration
of TCE, TCOH, or TCA. Several other
in vivo studies continued to report circulating
DCA in mice after TCE exposure (Abbas and
Fisher 1997; Greenberg et al. 1999). Fisher
et al. (1998) reported the results of a con-
trolled human exposure study in which DCA
was detected in some but not all human blood
samples. For all these studies, the extent to
which analytical artifacts of DCA remain is
unclear, so these data may be useful only for
upper bounds. However, even low DCA levels
may have toxicologic signiﬁcance.
Lash et al. (2000a) discussed two poten-
tial sources of DCA formation, from TCOH
and from dechlorination of TCA. [DCA does
not appear to be formed by gut microflora
(Moghaddam et al. 1996, 1997).] Merdink
et al. (2000) investigated dechlorination of
TCA and reported trapping a DCA radical
with the spin-trapping agent phenyl-tert-butyl
nitroxide, identiﬁed by gas chromatography/
mass spectroscopy, in both a chemical Fenton
system and rodent microsomal incubations
with TCA as substrate. On the other hand,
the work reviewed by Guengerich (2004) has
suggested that a source of DCA may be
through a TCE oxide (epoxide) intermediary.
Although oxidation of TCE by CYPs results
predominantly in CHL (in equilibrium with
CH) (Lash et al. 2000a), previous work of
Miller and Guengerich (1983) had reported
evidence of formation of the epoxide as
an independent oxidative pathway (i.e., not
leading to formation of CHL). In addition Cai
and Guengerich (1999) reported that a signiﬁ-
cant amount (about 35%) of DCA is formed
from aqueous decomposition of TCE oxide via
hydrolysis in an almost pH-independent man-
ner. Because this reaction forming DCA from
TCE oxide is a chemical process rather than a
process mediated by enzymes, and because evi-
dence suggests that some epoxide was formed
from TCE oxidation, Guengerich (2004)
noted that DCA would be an expected product
of TCE oxidation. 
Single doses of DCA are rapidly metabo-
lized by GST-ξ, but self-inhibition of this
metabolic pathway has been observed over
repeated exposures and has been quantiﬁed in
rodents (Barton et al. 1999; Gonzalez-Leon
et al. 1997, 1999; Schultz et al. 2002) and in
humans (Curry et al. 1991). Keys et al. (2004)
developed a PBPK model for DCA and its
self-inhibition of metabolism in rats and
mice. They reported that assuming a second
GST-ξ–independent clearance pathway sub-
stantially improved the fit to DCA time
courses, with the relative flux through this
pathway increasing with DCA dose because of
self-inhibition of GST-ξ; however, there
appears to be no other evidence for such a
pathway. The incorporation of DCA models
that include representations of the metabolism
and formation pathways into TCE models will
allow for evaluation of DCA-related dose met-
rics after TCE exposure, but a human PBPK
model for DCA has not yet been developed.
Pathways of glutathione conjugation and
subsequent metabolism. As discussed by
Caldwell and Keshava (2006), some GSH
metabolites of TCE are specific and potent
renal toxicants in vitro and in vivo, with effects
depending on both exposure concentration
and duration. However, Lash et al. (2000b)
noted that the processing of GSH conjugates is
complex and poorly understood relative to the
processing of oxidative metabolites, with a
number of different metabolites both locally
produced in the kidney and transported to the
kidney from the liver. In particular, quantita-
tive uncertainties exist in the production of
GSH conjugates from TCE, their interorgan
transport, and their subsequent processing
through bioactivation and detoxiﬁcation. 
The ﬁrst stable product of the conjugation
of TCE is DCVG, which is subsequently
processed to DCVC. Metabolic rate constants
have been measured in vitro for the conjuga-
tion of TCE with GSH (Lash et al. 1999a),
but data on the specific GST form/subunit
responsible are limited (see below), and no reli-
able protein recovery data exist to serve as the
basis for an in vitro to in vivo extrapolation of
metabolic rate constants for GSH conjugation.
Without such data, extrapolation of these
metabolic rate constants for application in
PBPK modeling–based approaches is highly
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rate of DCVG measured in isolated hepatocytes
was similar in order of magnitude to that mea-
sured for oxidative metabolites. Specifically,
Lipscomb et al. (1998) reported the Vmax for
oxidation to range from 6 to 41 (mean 16)
nmol/hr/million cells and Km values of 81–510
(mean, 266) ppm in headspace (n = 6). For the
GSH pathway, using similar experimental pro-
cedures, Lash et al. (1999a) measured rates of
DCVG production at concentrations from 25
to 10,000 ppm in headspace. Although rate
constants were not reported, they show maxi-
mal rates averaging around 10 nmol/hr/million
cells at concentrations around and above the
oxidation Km (250–7,000 ppm in headspace)
(n = 3) and an average rate of around 6 nmol/
hr/million cells (i.e., around half the maximal
rate) at 50 ppm (n = 3).
In addition a number of in vivo studies
provide evidence for the GSH pathway being
active in humans. Bernauer et al. (1996) and
Birner et al. (1993) reported measuring the
urinary metabolites of DCVC such as N-acetyl
DCVC in humans, which provided an indica-
tor of GSH conjugation, at least through the
N-acetyltransferase (NAT) detoxiﬁcation path-
way. Further evidence was found by Lash et al.
(1999b), who detected DCVG in the blood of
human volunteers exposed to TCE. However,
the subsequent conjugation product DCVC
was not detected in blood, and the correspond-
ing mercapturates were detected only sporadi-
cally in urine. Bloemen et al. (2001) measured
GSH pathway metabolites in the urine of
human volunteers and occupationally exposed
workers. Although Bloemen et al. (2001)
reported that levels were below detection limits
in all cases, their results appear to be consistent
with those of Bernauer et al. (1996). In partic-
ular, based on their detection limits, Bloemen
et al. (2001) place an upper bound of 0.05%
of TCE intake excreted in urinary GSH conju-
gates after 48 hr compared with about
18–27% excreted in urinary TCA + TCOH.
Taking the quotient of estimated TCA +
TCOH excreted to the upper bound of GSH
conjugates excreted gives a lower bound on this
excretion ratio of 360–540 to 1, which is
indeed lower than and hence consistent with
the estimated excretion ratio of 3,300–7,200
to 1 reported by Bernauer et al. (1996). 
DCVC is thought to be a critical interme-
diate in the fate of GSH conjugates of TCE.
Although one potential fate of DCVC is detox-
ification via NAT, bioactivation by renal
enzymes to a toxic form is a potential parallel
pathway. Thus, data on detoxiﬁcation do not
capture the total ﬂux through the GSH path-
way and are not informative regarding the
amount bioactivated (Lash et al. 2000a). It has
been hypothesized that bioactivation is through
the renal β-lyase metabolism of DCVC, pro-
ducing reactive metabolites that may contribute
to renal toxicity (Anders et al. 1988). In vitro
studies exist that measure human β-lyase activ-
ity in the kidney (Lash et al. 1990), but recent
in vitro data (Krause et al. 2003; Lash et al.
2003) indicate that ﬂavin-containing monooxy-
genases (FMOs) also may be toxicologically
important for the bioactivation of DCVC,
particularly in the human kidney. 
Moreover, DCVC may become available
to the kidney for bioactivation in multiple
ways, and thus far no attempt has been made
to model these complex interorgan processes.
GSH conjugates produced in the liver may be
exported directly to the blood into systemic
circulation or to the bile, where they can be
reabsorbed through the gut. Although the liver
is the primary site of GSH conjugation, most
tissues, including the kidney, contain GSTs
(Lash et al. 2000a), so the contribution to the
kidney of circulating DCVG produced in the
liver relative to local production of DCVG is
uncertain. In vitro studies (Cummings et al.
2000a, 2000b; Cummings and Lash 2000)
have reported GSH conjugation of TCE in rat
and human kidney cells, suggesting a role for
local metabolism. This work has also identiﬁed
several GST isoforms (mostly α class) in rat
kidney cells and reported measurable activity
toward TCE for those GSTs. Hissink et al.
(2002) examined GSTs isolated from human
liver and placenta and rat liver and kidney and
found activity of µ-class GSTs but no
detectable activity of α- or θ-class GSTs. Some
in vitro data also exist on competition between
TCE oxidation and conjugation (Lash et al.
1999a). GST activity was found not to dimin-
ish TCE oxidation, but CYP-mediated oxida-
tion substantially diminished conjugation. The
impact of variability in the GST pathway
among humans was also evaluated in this
in vitro study, but as mentioned above, extrapo-
lating this variability to the in vivo scenario
involves substantial uncertainty. 
Other extrahepatic metabolism. Although
it is generally thought that the liver is the
major site of TCE metabolism, CYPs, GSTs,
and other metabolizing enzymes are distribu-
ted at varying levels of activity throughout
other tissues (Lash et al. 2000a). Although
extrahepatic metabolism may not contribute
significantly to overall mass balance (Lash
et al. 2000a), it may be important locally in
terms of the toxicologic effects from in situ
production of metabolites. In addition to the
kidney, two potentially important sites are the
lung and the male reproductive system.
As discussed by Green (2000), the oxidative
pathway of TCE metabolism in mouse lung
Clara cells is hypothesized to be responsible for
the accumulation of CHL in mouse lungs,
leading to cytotoxicity [see also Odum et al.
(1992)]. Forkert and colleagues had previously
reported cytotoxicity in mouse lung Clara cells
from TCE exposure (Forkert and Birch 1989;
Forkert and Forkert 1994; Forkert et al. 1985).
Boers et al. (1999) reported the number of
Clara cells in the human lung and indicated
that Clara cells contribute substantially to cell
renewal and are important in the development
of lung adenocarcinoma in humans. Green
(2000) suggested that although the activity of
enzymes is lower in the lung as a whole than in
the liver, the activity of CYP in the lung appears
to be relatively higher than the activity of
enzymes involved in clearing CHL and TCOH
[believed to be alcohol dehydrogenase (ADH)
and uridine diphosphate-glucuronosyltrans-
ferase (UGT)]. Hence, these two metabolites
may accumulate in the mouse lung and lead to
toxicity. Green (2000) suggests that such a
mechanism in mice may not be relevant to
humans because there is little CYP2E1 activity
in the human lungs as a whole. However, meta-
bolic activity from whole lungs may give mis-
leading results because of the variety of cell
types in which high activity in a few may be
diluted by others with low activity, and the
activities of the relevant enzymes for either
CHL production or clearance in particular cell
types have not been examined to date. In addi-
tion the relative contribution between local
CHL production and circulating CHL (or CH),
which has been measured in high-dose TCE
exposures in mice (Abbas and Fisher 1997;
Greenberg et al. 1999; Prout et al. 1985) and
rats (Prout et al. 1985), has not been quantiﬁed. 
Reports of TCE exposure affecting the
male reproductive system, including the obser-
vation of Leydig cell tumors in rats exposed to
TCE (Maltoni et al. 1986, 1988), have led to
the investigation of metabolism and toxicity of
TCE and its metabolites in the male reproduc-
tive system. Forkert et al. (2002, 2003) report
several studies that indicate TCE oxidative
metabolism occurs in the male reproductive
tract. They detected CYP2E1 activity in the
epididymal epithelium and testicular Leydig
cells in mice, monkeys, and humans. Analysis
of seminal fluid from eight human subjects
diagnosed with clinical infertility and exposed
to TCE occupationally was also performed
and showed the presence of TCE, CHL, and
TCOH in all eight subjects, DCA in two sub-
jects, and TCA in one subject. TCA and/or
TCOH were identiﬁed in urine samples from
only two subjects. Although the lack of
detailed exposure information limits the use of
these data for development of a quantitative
pharmacokinetic understanding, this evidence
is qualitatively informative regarding the
potential for local metabolism of TCE in the
male reproductive tract.
PBPK Modeling of TCE 
and Its Metabolites
TCE has an extensive number of both in vivo
pharmacokinetic and PBPK modeling studies
[summarized in Supplemental Material, Tables
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members/2006/8691/suppl.pdf)]. Models
designed for risk assessment applications have
focused on descriptions of both TCE and
major oxidative metabolites TCA, TCOH,
and TCOG. Most of these models were exten-
sions of the models developed by Fisher and
co-workers (Allen and Fisher 1993; Fisher
et al. 1991) in rats, mice, and humans. These
models were based on a Ramsey and Andersen
(1984) structure with perfusion-limited tissue
compartments and equilibrium gas exchange,
saturable Michaelis-Menten kinetics for metab-
olism, and lumped volumes for the major cir-
culating oxidative metabolites TCA and
TCOH. Fisher and co-workers updated their
models with new in vivo and in vitro experi-
ments performed in mice (Abbas and Fisher
1997; Greenberg et al. 1999) and human vol-
unteers (Fisher et al. 1998) and summarized
their ﬁndings in Fisher (2000). Clewell et al.
(2000) did not include the updated Fisher data
but did use a wider set of in vivo and in vitro
mouse, rat, and human data than previous
models. In addition Clewell et al. (2000)
added EHR of TCOG and pathways for local
oxidative metabolism in the lung and GST
metabolism in the liver. Finally, Bois (2000a,
2000b) performed reestimations of PBPK
model parameters for the Fisher and Clewell
models using a Bayesian population approach
(e.g., Gelman et al. 1996). 
As discussed by Rhomberg (2000), using
the models of Fisher (2000), Clewell et al.
(2000), and Bois (2000a, 2000b) for cross-
species extrapolation of rodent cancer bioas-
says led to sometimes substantially different
quantitative results. One important difference
is that model calibrations were based on differ-
ent subsets of the database [summarized in
Supplemental Material, Tables S-1 and S-2
(http://www.ehponline.org/members/2006/
8691/suppl.pdf)]. The Clewell model was
based primarily on a variety of data published
before 1995, the Fisher models were based pri-
marily on new studies conducted by Fisher
and co-workers, as described above, and the
Bois reestimations added to the Clewell data
set but did not include some of the new Fisher
data. In addition the Clewell model differed
structurally in its use of single-compartment,
volume-of-distribution models for metabolites
compared with the Fisher models’ use of mul-
tiple physiologic compartments. Also, the
Clewell model but not the Fisher models
included EHR of TCOH/TCOG (although
reabsorption was set to zero in some cases).
Finally, the Bayesian statistical analysis used
by Bois led to some differences in parameter
estimates because all parameters were allowed
to vary simultaneously compared with only a
select few.
Given all these differences, it is not surpris-
ing that the different models led to different
quantitative results. Even among the Fisher
models themselves, Fisher (2000) noted in-
consistencies, including differing estimates for
metabolic parameters between mouse gavage
and inhalation experiments. Possible explana-
tions for these inconsistencies include the
impact of corn oil vehicle use during gavage
(Staats et al. 1991) and the impact of a
decrease in ventilation rate in mice due to sen-
sory irritation during the inhalation of solvents
(e.g., Stadler and Kennedy 1996). 
Throughout 2004 the U.S. EPA and the
U.S. Air Force jointly sponsored an integration
of the Fisher, Clewell, and Bois modeling
efforts (Clewell et al. 2004). In brief, a single
interim model structure combining features
from both the Fisher and Clewell models was
developed and used for all three species of
interest (mice, rats, and humans). An effort
was made to combine structures in a manner as
simple as possible; the evaluation of most alter-
native structures was left for future work.
However, species- and dose-dependent TCA
plasma binding was implemented, although
only the in vitro study of Lumpkin et al.
(2003) was used as parameter inputs. A hierar-
chical Bayesian population analysis similar to
the Bois (2000a, 2000b) analyses was per-
formed on the revised model with a cross-
section of the combined database of kinetic
data to provide estimates of parameter uncer-
tainty and variability (Hack et al. 2004, in
press). Particular attention was given to using
data from each of the different efforts, but
because of time and resource constraints, a
combined analysis of all data was not per-
formed. The results from this effort suggested
that a single model structure could provide rea-
sonable fits to a variety of data evaluated for
TCE and its major oxidative metabolites TCA,
TCOH, and TCOG. However, in many cases,
different parameter values—particularly for
metabolism—were required for different stud-
ies, indicating significant interindividual or
interexperimental variability. In addition it was
concluded that dosimetry of DCA, conjugative
metabolites, and metabolism in the lung
remained highly uncertain (Clewell et al. 2004). 
Although recent PBPK modeling studies
have attempted to integrate different data sets,
several research needs can be suggested for
future work. Typically, PBPK models predict
the concentration of chemicals at the target
organ, making it possible to start linking dose
metrics with pharmacodynamic effects.
Caldwell and Keshava (2006) have reviewed
additional factors that modulate the MOA of
TCE that could be correlated with an appro-
priate dose metric predicted from a PBPK
model. In addition a generalized PBPK model
structure can be developed that integrates a
larger fraction of the in vivo data sets in 
the published literature [summarized in
Supplemental Material, Tables S-1 and S-2
(http://www.ehponline.org/members/2006/
8691/suppl.pdf)]. Finally, with additional
effort PBPK modeling can be applied to TCE
in chemical mixtures, taking into account
changes in metabolism induced by TCE
itself, other solvents, disinfection by-products,
and ethanol. 
Conclusions 
Studies of the pharmacokinetics of TCE and
its metabolites have been conducted for more
than 30 years. Many early PBPK modeling
efforts provided only a description of TCE
itself and did not include any metabolites.
Such models are still used for particular appli-
cations such as neurotoxicology (Boyes et al.
2005; Simmons et al. 2002), understanding
the tissue distribution of TCE (Albanese et al.
2002; Keys et al. 2003), or assessing pharmaco-
kinetic interactions of mixtures (Dobrev et al.
2001). Models that include metabolite descrip-
tions have focused primarily on TCE and its
major circulating oxidative metabolites TCA
and TCOH, and its glucuronide, with some
attempt at quantifying other metabolic path-
ways with potential toxicological importance
(Clewell et al. 2000; Fisher 2000). Finally, a
number of recent modeling efforts have sought
to integrate the body of existing pharmaco-
kinetic information on TCE and its metabo-
lites (Bois 2000a, 2000b; Clewell et al. 2004;
Hack et al. 2004, in press), highlighting both
apparent variability and some inconsistencies
among studies across the database. 
For risk assessment it is particularly impor-
tant to characterize the impact of both vari-
ability (i.e., irreducible heterogeneity) and
uncertainty (i.e., lack of knowledge) on toxi-
cologically relevant dosimetry. Although
PBPK modeling in risk assessment is intended
to provide more accurate estimates of dose
relative to default procedures, it should be rec-
ognized that in some cases, rigorous analysis of
PBPK models may reveal uncertainties not
previously considered or of greater magnitude
than that which is assumed under default pro-
cedures. Even for TCE, TCA, and TCOH, a
number of structural hypotheses remain to be
tested, and some inconsistencies can be better
understood. However, a large database of
information exists on the pharmacokinetics of
these three chemicals in mice, rats, and
humans, and statistical methods such as hier-
archical Bayesian population modeling and
computation tools such as Markov chain
Monte Carlo analyses are now available to
conduct complex analyses of parameter and
model sensitivity and uncertainty [e.g., see dis-
cussion in Bernillon and Bois (2000)].
Therefore, even if these remaining uncertain-
ties cannot yet be resolved, it appears feasible,
at least in principle, to characterize their effect
on risk assessment quantitatively while at the
same time providing insight into potential
Chiu et al.
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Furthermore, given the number of studies
conducted in different individuals, characteriza-
tion of interindividual variability for TCE,
TCA, and TCOH pharmacokinetics also
appears feasible. Although extrapolation from
human volunteers to the broader human popu-
lation presents some additional uncertainties, in
some cases in vitro data may be useful to inform
this inference. Thus, the challenge for TCE,
TCA, and TCOH is primarily in implementa-
tion—that is, the practical difﬁculties of analyz-
ing a large database of information against a
number of different hypotheses. Unfortunately,
the pharmacokinetics database is much more
sparse, particularly in terms of reliable in vivo
data, for several metabolites of toxicological
interest, including DCA, local production and
clearance of CHL in the lung, and conjugative
metabolites. Thus, the challenge in these cases
is whether, given the current lack of ability to
verify pharmacokinetics in vivo, either in vitro
data or better calibrated (but potentially less
toxicologically relevant) dose surrogates exist
that could provide sufﬁciently reliable informa-
tion for application to risk assessment. 
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